RE: Stick this link through google translate2 Dec 2019 09:58
Faron Pharmaceuticals , listed in November 2015 on the AIM marketplace of London Stock Exchange growth companies, is planning a parallel listing on First North in Helsinki. CEO Markku Jalkanen says that the purpose of parallel listing is to serve Finnish investors.
“More than half of the shareholders are Finnish and the exchange has proved technically difficult,” Jalkanen says.
In London, DI certificates are traded. They cannot be held by a Finnish investor for a long time and it has been difficult to convert to direct shares. Jalkanen expects that easing trading will improve the liquidity of the share.